Piper Sandler Reaffirms Their Buy Rating on Evolent Health (EVH)

Jul 3, 2023  · Piper Sandler analyst Jessica Tassan reiterated a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of $51.00. The company’s shares closed last …


Install CouponFollow Chrome Extension   CouponFollow Extension

$51.00
OFF

Piper Sandler Reaffirms Their Buy Rating On Evolent Health (EVH)

2 weeks from now

Jul 3, 2023  · Piper Sandler analyst Jessica Tassan reiterated a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of $51.00. The company’s shares closed last …

businessinsider.com

$51.00
OFF

Analysts Are Bullish On Top Healthcare Stocks: Evolent Health (EVH ...

2 weeks from now

Jun 13, 2023  · In a report released today, Jessica Tassan from Piper Sandler reiterated a Buy rating on Evolent Health, with a price target of $51.00. The company’s shares closed last …

businessinsider.com

$51
OFF

Piper Sandler Reaffirms Their Buy Rating On Evolent Health (EVH ...

2 weeks from now

Feb 23, 2024  · Piper Sandler analyst Jessica Tassan reiterated a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of $51...

businessinsider.com

$51.00
OFF

Piper Sandler Reiterates Overweight Rating On Evolent Health (EVH)

2 weeks from now

Apr 17, 2024  · Piper Sandler analyst Jessica Tassan reiterated an Overweight rating and $51.00 price target on Evolent Health (NYSE: EVH).The analyst commented, "We identify unnamed …

streetinsider.com

$38
OFF

Piper Sandler Maintains Evolent Health(EVH.US) With Buy Rating, …

2 weeks from now

Dec 6, 2024  · PiperSandler analyst Jessica Tassan maintains $Evolent Health(EVH.US)$ with a buy rating, and adjusts the target price from $38 to $18.According to TipRanks data, the ...

moomoo.com

$38.00
OFF

Piper Sandler Reiterates Overweight Rating On Evolent Health (EVH)

2 weeks from now

Aug 22, 2024  · Piper Sandler analyst Jessica Tassan reiterated an Overweight rating and $38.00 price target on Evolent Health (NYSE: EVH).The analyst comments "Reuters reports that EVH …

streetinsider.com

$37
OFF

Piper Sandler Adjusts Evolent Health's Price Target To $37 From …

2 weeks from now

-- Evolent Health has an average rating of buy and price targets ranging from $37 to $44, according to analysts polled by Capital IQ. Price: 28.44, Change: +0.42, Percent Change: +1.5 ...

marketscreener.com

$37
OFF

Piper Sandler Adjusts Evolent Health's Price Target To $37

2 weeks from now

05:52AM EDT, 04/25/2022 (MT Newswires) -- Evolent Health (EVH) has an average rating of buy and price targets ranging from $37 to $44, according to analysts polled by Capital IQ. (MT …

moomoo.com

$0.30
OFF

Evolent Health, Inc. (EVH) Latest Stock News - Seeking Alpha

2 weeks from now

Dec 31, 2024  · Piper Sandler bullish on Evolent Health, Omnicell, Health Catalyst SA News Wed, Nov. 22, 2023 Evolent Health Non-GAAP EPS of $0.30 beats by $0.20, revenue of $511M …

seekingalpha.com

$35
OFF

Piper Sandler Maintains Overweight On Evolent Health, Raises

2 weeks from now

Aug 3, 2022  · Piper Sandler analyst Jessica Tassan maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $35 to $40.

benzinga.com

$51
OFF

Piper Sandler Remains A Buy On Evolent Health (EVH)

2 weeks from now

Dec 5, 2023  · Piper Sandler analyst Jessica Tassan reiterated a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of $51...

businessinsider.com

$35
OFF

Piper Sandler Maintains Overweight On Evolent Health, Raises

2 weeks from now

Piper Sandler analyst Jessica Tassan maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $35 to $40. Recommended What's Needed for Stocks to Rally …

moomoo.com

$18.00
OFF

Analysts Offer Insights On Healthcare Companies ... - Markets Insider

2 weeks from now

Dec 5, 2024  · Evolent Health (EVH) Piper Sandler analyst Jessica Tassan maintained a Buy rating on Evolent Health today and set a price target of $18.00.The company’s shares closed …

businessinsider.com

$37
OFF

Piper Sandler Adjusts Evolent Health's Price Target To $37 From …

2 weeks from now

-- Evolent Health has an average rating of buy and price targets ranging from $37 to $44, according to analysts polled by Capital IQ. Price: 28.44, Change: +0.42, Percent Change: +1.5 …

marketscreener.com

$45.00
OFF

Evolent Health’s Strong Financial Performance And Positive Market ...

2 weeks from now

Nov 6, 2023  · David Larsen, an analyst from BTIG, maintained the Buy rating on Evolent Health (EVH – Research Report). The associated price target is $45.00. The associated price target …

businessinsider.com

$149.00
OFF

Piper Sandler Reaffirms Their Buy Rating On Valero Energy (VLO)

2 weeks from now

1 day ago  · In a report released today, Ryan Todd from Piper Sandler maintained a Buy rating on Valero Energy (VLO – Research Report), with a price target of $149.00. The company’s …

businessinsider.com

FAQs about Piper Sandler Reaffirms Their Buy Rating on Evolent Health (EVH) Coupon?

Should you buy evolent health (EVH) Piper Sandler?

Evolent Health (EVH) Piper Sandler analyst Jessica Tassan maintained a Buy rating on Evolent Health today and set a price target of $18.00. The company’s shares closed last Thursday at $11.30, close to its 52-week low of $11.17. According to TipRanks.com, Tassan is a 1-star analyst with an average return of -1.8% and a 46.8% success rate. ...

Should you buy evolent health (EVH – research report)?

Piper Sandler analyst Jessica Tassan reiterated a Buy rating on Evolent Health ( EVH – Research Report) today and set a price target of $51.00. The company’s shares closed last Friday at $30.30. According to TipRanks, Tassan is a 3-star analyst with an average return of 5.0% and a 54.79% success rate. ...

Will Piper Sandler buy evolent health & Omnicell?

Piper Sandler said it would be buyers of Evolent Health ( NYSE: EVH ), Omnicell ( NASDAQ: OMCL) and Health Catalyst ( NASDAQ: HCAT) moving into 2024 and its annual healthcare conference next week, according to a recent note. ...

Should you buy PIPR Piper Sandler companies (PIPR)?

PIPR Piper Sandler Companies (PIPR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. ...

How much will Piper Sandler companies earn in 2025?

For the fiscal year ending December 2025, this company is expected to earn $14.14 per share, which is a change of 11.4% from the year-ago reported number. Analysts have been steadily raising their estimates for Piper Sandler Companies. Over the past three months, the Zacks Consensus Estimate for the company has increased 5%. ...

Will Piper Sandler companies (PSP) move higher in the near term?

The upgrade of Piper Sandler Companies to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. Want the latest recommendations from Zacks Investment Research? ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension